Investigation of Blood-Based Biomarkers for the Diagnosis of Episodic and Chronic Migraine Compared with Healthy Non-Migraine Controls (The Migraine Blood Test Research Study)

Recruiting

• Conditions: Migraine; Neurological - Other neurological disorders

• Registration Number: ACTRN12618001951246
• Lead Sponsor: The University of Adelaide

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-12-03
• Last Update Posted: 10 December 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Healthy Participants:
1. No history of migraine.
2. Otherwise in good general health (including only non-problematic headaches (if any)).

Migraine participants:
Diagnostic criteria will be from The International Classification of Headache Disorders, 3rd Edition; The International Headache Society, Cephalagia, 2018: 38, 1-211.
1. Episodic migraine, with or without aura, where individuals experience an average of at least 2 episodes of migraine per month in the last 3 months.
2. Chronic migraine, where individuals experience an average of at least 15 days of headache per month of which at least 8 days of migraine per month for the last 3 months. Chronic migraine participants are eligible with or without concomitant medication overuse.
3. Otherwise in good general health.

Exclusion Criteria

1. Presence of an inflammatory process, or clinically significant infection in the last 4 weeks.
2. Immunisation within the last 4 weeks.
3. Clinically significant renal, hepatic, cardiac, autoimmune disease.
4. Current use of immunosuppressant medication, such as systemic corticosteroid, hydroxychloroquine, methotrexate or azathioprine.
5. Inability to read or comprehend the written information provided.
6. Current use of medications known to affect TLR responsiveness, including amitriptyline.
7. Current pregnancy.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proteomic analyses and hyperspectral imaging techniques will be used to identify potential novel blood biomarkers for the diagnosis of migraine. These biomarkers are of an exploratory nature. <br>[At the time of blood sampling (baseline). ]

Secondary Outcome Measures

Name	Time	Method
il[Nil]